CN100463690C - 中药袋泡茶 - Google Patents
中药袋泡茶 Download PDFInfo
- Publication number
- CN100463690C CN100463690C CNB200510061745XA CN200510061745A CN100463690C CN 100463690 C CN100463690 C CN 100463690C CN B200510061745X A CNB200510061745X A CN B200510061745XA CN 200510061745 A CN200510061745 A CN 200510061745A CN 100463690 C CN100463690 C CN 100463690C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- tea
- radix
- medicine bag
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 241001122767 Theaceae Species 0.000 title 1
- 244000269722 Thea sinensis Species 0.000 claims abstract description 22
- 235000009569 green tea Nutrition 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 4
- 241000628997 Flos Species 0.000 claims description 14
- 235000013616 tea Nutrition 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 238000007603 infrared drying Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 3
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 240000005979 Hordeum vulgare Species 0.000 abstract 1
- 235000007340 Hordeum vulgare Nutrition 0.000 abstract 1
- 241000735234 Ligustrum Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 241000731475 Trachycarpus Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229910052683 pyrite Inorganic materials 0.000 description 3
- 239000011028 pyrite Substances 0.000 description 3
- RIXNFYQZWDGQAE-DFHVBEEKSA-N (4as,6ar,6as,6br,8ar,10s,12ar,14bs)-10-acetyloxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C([C@H]1C2=CC[C@H]34)C(C)(C)CC[C@]1(C(O)=O)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)C)C1(C)C RIXNFYQZWDGQAE-DFHVBEEKSA-N 0.000 description 2
- PHFUCJXOLZAQNH-OTMOLZNZSA-N Acetylursolic acid Chemical compound C1C[C@H](OC(C)=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PHFUCJXOLZAQNH-OTMOLZNZSA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 239000010282 Emodin Substances 0.000 description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 102000006995 beta-Glucosidase Human genes 0.000 description 2
- 108010047754 beta-Glucosidase Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- KUBCEEMXQZUPDQ-UHFFFAOYSA-N hordenine Chemical compound CN(C)CCC1=CC=C(O)C=C1 KUBCEEMXQZUPDQ-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- STKUCSFEBXPTAY-KCWGXYKVSA-N nuezhenoside Natural products COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=CC)[C@@H]1CC(=O)OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O STKUCSFEBXPTAY-KCWGXYKVSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- NIFIFKQPDTWWGU-UHFFFAOYSA-N pyrite Chemical compound [Fe+2].[S-][S-] NIFIFKQPDTWWGU-UHFFFAOYSA-N 0.000 description 2
- -1 pyrite glycoside Chemical class 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- WEHXAEGTVPWKDY-UHFFFAOYSA-N toralactone Chemical compound C1=C(C)OC(=O)C=2C1=CC1=CC(OC)=CC(O)=C1C=2O WEHXAEGTVPWKDY-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- NULBHTHMVOCGOE-ZBCCAYPVSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-3-[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@H](OC=2C=C3C(C(C=C(O3)C=3C=CC(O)=CC=3)=O)=C(O)C=2)O1 NULBHTHMVOCGOE-ZBCCAYPVSA-N 0.000 description 1
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 206010065558 Aortic arteriosclerosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- CBOKHFLBNZMMAA-UHFFFAOYSA-N Emodin anthrone Natural products OC1=CC(O)=CC2=CC3=CC(C)=CC(O)=C3C(O)=C21 CBOKHFLBNZMMAA-UHFFFAOYSA-N 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000019468 Iatrogenic Disease Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- CFLNHFUPWNRWJA-UHFFFAOYSA-N Obtusin Chemical group O=C1C2=CC(C)=C(O)C(OC)=C2C(=O)C2=C1C=C(OC)C(OC)=C2O CFLNHFUPWNRWJA-UHFFFAOYSA-N 0.000 description 1
- OBBJQZSMXOJMCN-UHFFFAOYSA-N Obtusin Natural products COc1cc2C=CC(=O)Oc2c3OCC(Oc13)C(=C)C OBBJQZSMXOJMCN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 208000001792 Sarcoma 37 Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- PHFUCJXOLZAQNH-UHFFFAOYSA-N Ursolic acid acetat Natural products C1CC(OC(C)=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(C)C5C4=CCC3C21C PHFUCJXOLZAQNH-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 201000001962 aortic atherosclerosis Diseases 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 108010089934 carbohydrase Proteins 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- LAJSXCAVRQXZIO-UHFFFAOYSA-N emodin anthrone Chemical compound C1=C(O)C=C2CC3=CC(C)=CC(O)=C3C(=O)C2=C1O LAJSXCAVRQXZIO-UHFFFAOYSA-N 0.000 description 1
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 description 1
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 description 1
- 235000011797 eriodictyol Nutrition 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229940071490 hordenine Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 235000011576 oleuropein Nutrition 0.000 description 1
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 1
- 229940026509 theaflavin Drugs 0.000 description 1
- 235000008118 thearubigins Nutrition 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种中药袋泡茶,尤其是涉及一种对高血压、高血脂以及心血管疾病有明显改善和预防作用的袋泡茶;其技术方案为:决明子10%~25%、棕榈花8%~25%、槐米5%~20%、女贞子1%~15%、生大黄7%~25%、生麦芽3%~20%、绿茶1%~10%、生甘草5%~20%,各组分总和为100%;其加工步骤为:(1)精选各组分原料,保证质地清洁,含水量低于5%;(2)将各组分材料按比例混合后,粉碎至粒度约5~50mm;(3)再进行粉碎至粒度约0.1~5mm,其后进行细度粉碎,最终粒度约0.1mm;(4)红外线干燥、灭菌;(5)称量、分装、封袋即可。
Description
技术领域
本发明涉及一种中药袋泡茶,尤其是涉及一种对高血压、高血脂,以及心血管疾病有明显改善和预防作用的袋泡茶。
背景技术
随着社会进步,经济水平的提高,心血管疾病已经成为威胁人类生命和健康的“头号杀手”,心脑血管病的发生原因主要是高血压、高血脂,患者因为长期服用治疗心血管疾病或者高血压、高血脂等慢性病的药物,多会产生抗药反应、药物过敏,甚至是酿成一些医源性疾病,而对于病情较轻,病时长,一时难以痊愈的患者来说,长期使用化学药品或抗生素类药品,副作用相对于疗效更为明显,因此,人们对于这类慢性病除了坚持药物治疗外,越来越多的采取有针对性的饮用药茶作为辅助治疗手段,一方面可以起到良好的辅助治疗作用,另一方面可以起到养生保健的作用。
发明内容
本发明主要是提供一种对高血压、高血脂,以及心血管疾病有明显改善和预防作用的中药袋泡茶。
本发明的上述目的主要是通过下述技术方案得以实现的:中药袋泡茶,由以下组分按重量百分比组成——决明子10%~25%、棕榈花8%~25%、槐米5%~20%、女贞子1%~15%、生大黄7%~25%、生麦芽3%~20%、绿茶1%~10%、生甘草5%~20%,各组分总和为100%。获得所述袋泡茶成品的加工步骤为:(1)精选各组分原料,保证质地清洁,含水量低于5%;(2)将各组分材料按比例混合后,粉碎至粒度约5~50mm;(3)再进行粉碎至粒度约0.1~5mm,其后进行细度粉碎,最终粒度约0.1mm;(4)红外线干燥、灭菌;(5)称量、分装、封袋即可。由于药物被粉碎至微粒,其表面面积远大于煎煮时,与水的接触面积亦随之增大,有效成分易溶出,饮用时沸水冲泡,以茶杯为容器,因保温性能好,通常能使水温在一段时间内维持在80℃~95℃,这样可保证有效成分的充分溶出而又不被破坏。
作为优选,所述各组分的重量配比最好是:决明子20%、棕榈花20%、槐米15%、女贞子5%、生大黄15%、生麦芽10%、绿茶5%、生甘草10%,各组分总和为100%。
本发明所述的中药袋泡茶配方中各组分药性药理:
a:决明子——甘、苦、微寒、入肝经,主要成分为决明素、决明内酯、维生素A、大黄酚、大黄素、大黄酸、大黄素蒽酮,有清肝明目、降压和降低血清胆固醇的作用,并且能抑止主动脉粥样硬化斑块的形成,因此对防治血管硬化与高血压有显著效果;
b:棕榈花——味涩,性凉,归肝、脾经,燥湿解毒、收敛止血。
c:槐米——味苦、凉寒入心肝肠四经,由于槐米茶中芦丁黄铜甙含量高达21.0%,黄铜甙能促进微血管循环,保持毛细血管正常的抵抗力,减少血管的通透性,可使因脆性增加而出血的毛细血管恢复正常弹性,故能软化血管、降血压、增加血管弹性,还能有效降低肝、主动脉及血液中胆固醇含量;另外在对心血管作用方面,槐米中所含黄铜甙、槲皮素可扩涨冠状动脉,改善微循环,目前人工合成的许多黄铜衍化物,多有扩涨冠状动脉及抗心律不齐,其制剂有促进微循环、降脂降压作用;
d:女贞子——含女贞苷、10-羟基女贞苷、橄榄苦苷、槲皮素、外消旋圣草素、齐墩果酸、乙酰齐墩果酸、熊果酸、乙酰熊果酸、女贞子酸、女贞苷酸、β-谷甾醇等;药理研究表明,女贞子具有抗炎和促进免疫功能的作用——女贞子水煎剂对二甲苯引起的小鼠耳廓肿胀、醋酸引起的小鼠腹腔毛细血管通透性增加及角叉莱胶、蛋清、甲醛性大鼠足跖肿胀均有明显抑制作用。对免疫功能的影响则表现在其水煎剂连续灌胃可使幼年小鼠胸腺、脾脏重量明显增加;
e:大黄——药性苦、寒,归脾、胃、大肠、肝、胆经,含大黄酚、大黄酸、芦荟大黄素等蒽醌类约30%,鞣质约5%,药理试验表明,使用大黄的粗提取物进行皮下注射,对小鼠肉瘤-37有直接伤害能力;大黄素和大黄酸对小鼠黑色素瘤、淋巴肉瘤、乳腺癌及艾氏腹水癌均有明显的抑制作用;对癌细胞直接破坏作用,可使血压下降,浸液口服有降低血清高胆固醇的作用;中医多用于败毒抗癌、泻热导积、消肿逐淤;
f:生麦芽——主要含淀粉酶、转化糖酶、氧化酶、催化酶、纤维二糖酶、龙胆二糖酶、大麦芽碱约,卵磷脂,氨基酸,以及细胞色素C,对于胆固醇有溶解作用,可降血压,同时还具有提神、健脾、开胃等作用;
g:绿茶中的黄烷醇是治疗冠心病的主要药物成分,茶红素和茶黄素,能有效地抑制血管紧张的活性(血管紧张素是造成目前大多数高血压患者血压升高不下的主要因素),绿茶中的咖啡碱和儿茶素还具有使血管壁松驰令血管壁保持足够的弹性、增加血管有效直径的作用,由于绿茶具有抗凝、促溶、抑制血小板的聚积、降低血脂,增高a脂蛋白、改善血液中的胆固醇和磷脂的比值等功效,可以减少动脉血管和冠脉内壁上斑块的的形成,达到改善和抗动脉硬化、活血化瘀、防治心血管疾病的目的。
因此,本发明是取药物之性,饮茶之味,两者配伍,相辅相成,具有配方合理,制作简便易行,有效成分的溶出量大,服用后易被机体吸取,作用迅速等优点,长期饮用此中药袋泡茶,可以稳定血压,改善脑血流,预防中风的发生,对高血压、高血脂及心血管疾病患者有预防、辅助治疗,并对人体有滋补作用,饮用方便。
具体实施方式
下面通过实施例,对本发明的技术方案作进一步具体的说明。
实施例:以每生产100Kg中药袋泡茶为例——精选决明子20Kg、棕榈花20Kg、槐米15Kg、女贞子5Kg、生大黄15Kg、生麦芽10Kg、绿茶5Kg、生甘草10Kg,保证各组分质地清洁,含水量低于5%;将各组分材料均匀混合后,粉碎至粒度约5~50mm;进行第二次粉碎,至粒度在0.1~5mm之间,其后进行细度粉碎,最终粒度约0.1mm;进行红外线干燥、灭菌;称量、分装、封袋即可。
最后,应当指出,以上实施例仅是本发明较有代表性的例子。显然,本发明的技术方案并不限于上述实施例,还可以有许多变形。本领域的普通技术人员能从本发明公开的内容直接导出或联想到的所有变形,均应认为是本发明的保护范围。
Claims (3)
1.一种中药袋泡茶,其特征在于由以下组分按重量百分比组成:决明子10%~25%、棕榈花8%~25%、槐米5%~20%、女贞子1%~15%、生大黄7%~25%、生麦芽3%~20%、绿茶1%~10%、生甘草5%~20%、各组分总和为100%。
2.根据权利要求1所述的中药袋泡茶,其特征在于各组分重量百分比组成:决明子20%、棕榈花20%、槐米15%、女贞子5%、生大黄15%、生麦芽10%、绿茶5%、生甘草10%、各组分总和为100%。
3.根据权利要求1所述的中药袋泡茶,其特征在于获得所述袋泡茶成品的加工步骤为:
(1)精选各组分原料,保证质地清洁,含水量低于5%;
(2)将各组分材料按比例混合后,粉碎至粒度为5~50mm;
(3)再进行粉碎至粒度为0.1~5mm,其后进行细度粉碎,最终粒度为0.1mm;
(4)红外线干燥、灭菌;
(5)称量、分装、封闭即可。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200510061745XA CN100463690C (zh) | 2005-11-30 | 2005-11-30 | 中药袋泡茶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200510061745XA CN100463690C (zh) | 2005-11-30 | 2005-11-30 | 中药袋泡茶 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1977954A CN1977954A (zh) | 2007-06-13 |
CN100463690C true CN100463690C (zh) | 2009-02-25 |
Family
ID=38129374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200510061745XA Expired - Fee Related CN100463690C (zh) | 2005-11-30 | 2005-11-30 | 中药袋泡茶 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100463690C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105166146A (zh) * | 2015-09-14 | 2015-12-23 | 贵州大自然科技股份有限公司 | 一种棕榈多酚红茶及其制备方法 |
CN105145940A (zh) * | 2015-09-14 | 2015-12-16 | 贵州大自然科技股份有限公司 | 一种棕榈多酚绿茶及其制备方法 |
CN105166179A (zh) * | 2015-09-14 | 2015-12-23 | 贵州大自然科技股份有限公司 | 一种棕榈花香红茶及其制备方法 |
CN106954702A (zh) * | 2016-01-12 | 2017-07-18 | 蔡德成 | 一种具有保健作用的孔雀草袋泡茶及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1478508A (zh) * | 2002-12-31 | 2004-03-03 | 临沂新时代药业有限公司 | 一种治疗脂肪肝的中药组合物及其制备方法 |
-
2005
- 2005-11-30 CN CNB200510061745XA patent/CN100463690C/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1478508A (zh) * | 2002-12-31 | 2004-03-03 | 临沂新时代药业有限公司 | 一种治疗脂肪肝的中药组合物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
国内降血脂中草药研究概况. 彭悦.中国中药杂志,第8卷第1期. 1983 |
国内降血脂中草药研究概况. 彭悦.中国中药杂志,第8卷第1期. 1983 * |
Also Published As
Publication number | Publication date |
---|---|
CN1977954A (zh) | 2007-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103861060B (zh) | 一种解酒片及其制备方法 | |
CN1954686B (zh) | 一种降低血脂的茶饮料及其制备方法 | |
WO2010054520A1 (zh) | 净化血管的药物组合物及其制备方法 | |
CN101543248A (zh) | 一种特别适合“三高一酸”人群饮用的凉茶及其制备方法 | |
CN100463690C (zh) | 中药袋泡茶 | |
CN103891962B (zh) | 一种美容瘦身的保健茶及其制备方法 | |
CN104524146A (zh) | 一种预防和辅助治疗“三高症”中药组合物及其应用 | |
KR101520332B1 (ko) | 천연물 약재가 함유된 기능성 커피 및 이의 제조방법 | |
CN102600358A (zh) | 一种润肠通便的中药及其制品 | |
CN107494817A (zh) | 一种降糖降脂茶 | |
CN102697843B (zh) | 一种清肠通便排毒养颜保健品及其制备方法 | |
CN106390077A (zh) | 一种治疗腹痛、腹泻的药物组合物及其制备方法和应用 | |
KR20160014075A (ko) | 백수오를 포함한 차 및 그 제조방법 | |
CN105833011A (zh) | 一种保健药酒 | |
CN102462787B (zh) | 治疗高血压、改善高血脂的中药组合物及其制剂方法 | |
CN109260320A (zh) | 一种茶多酚和中药提取物的组合物和用途 | |
CN104146302A (zh) | 一种蓝莓果汁饮品 | |
CN104187979A (zh) | 一种哈密瓜饮料 | |
CN103960415A (zh) | 一种减肥保健凉茶及其制备方法 | |
CN1434717A (zh) | 一种减肥药及其制备和应用 | |
KR20130102181A (ko) | 향부자를 이용한 차 및 그 제조방법 | |
CN105724694A (zh) | 一种美白祛斑花草茶 | |
CN105796971A (zh) | 一种治疗脂肪肝的中药制剂及其制作方法 | |
CN100355434C (zh) | 一种防治心脑血管疾病的药物 | |
CN104543221A (zh) | 一种舒筋茶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090225 |